Literature DB >> 33875434

Human Tissue Distribution of Anidulafungin and Micafungin.

Jana Marx1, René Welte1, Tiziana Gasperetti1, Patrizia Moser2, Michael Joannidis3, Romuald Bellmann1.   

Abstract

Concentrations of anidulafungin and micafungin were determined in eight different tissues obtained during autopsy of four deceased individuals who had been treated with anidulafungin and of seven who had received micafungin. The largest amounts were recovered from liver, with anidulafungin concentrations of 11.01 to 66.50 μg/g and micafungin levels of 0.36 to 5.53 μg/g (0.65 μg/g 30 days after the last administration). The lowest anidulafungin levels were measured in skeletal muscle, and the lowest micafungin concentrations were in kidneys.

Entities:  

Keywords:  antifungal target-site penetration; echinocandins; invasive candidiasis; tissue distribution

Mesh:

Substances:

Year:  2021        PMID: 33875434      PMCID: PMC8218649          DOI: 10.1128/AAC.00169-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

Authors:  Helene Vogelsinger; Stefan Weiler; Angela Djanani; Jordan Kountchev; Rosa Bellmann-Weiler; Christian J Wiedermann; Romuald Bellmann
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

2.  Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Authors:  Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

3.  Pharmacokinetics and tissue distribution of anidulafungin in rats.

Authors:  Bharat Damle; Martin Stogniew; James Dowell
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

4.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

Review 5.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

6.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

7.  In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.

Authors:  Erika J Ernst; Ellen E Roling; C Rosemarie Petzold; Douglas J Keele; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate.

Authors:  N Collette; P van der Auwera; A P Lopez; C Heymans; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

10.  ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Authors:  Frederic Tissot; Samir Agrawal; Livio Pagano; Georgios Petrikkos; Andreas H Groll; Anna Skiada; Cornelia Lass-Flörl; Thierry Calandra; Claudio Viscoli; Raoul Herbrecht
Journal:  Haematologica       Date:  2016-12-23       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.